Zurich, Switzerland, 21 March, 2022 – Versantis, a clinical-stage biotechnology company developing novel therapies for orphan and pediatric liver diseases, today announced that Stan Bukofzer, MD, has become a scientific advisor to the company.
After the establishment of a wholly-owned US subsidiary in December 2021, and the appointment of Mark Fitzpatrick as Versantis’ US-based CEO, the company plans to engage in US focused regulatory and clinical activities related to its lead investigational product candidate, VS-01 in patients with acute-on-chronic liver failure (ACLF). ACLF is a rare disease for which there is no approved treatment.
Dr. Bukofzer is a US-based, seasoned pharmaceutical executive with C-Suite experience in private and public companies, working across the full drug life-cycle from discovery to commercialization. As a trained gastro-hepatologist, he has particular interest in developing drugs to treat patients with late-stage liver disease, including developing novel therapies for treating hepatic encephalopathy and hepatorenal syndrome.
In his current role as Chief Scientific & Medical Officer (CS&MO) and foundational member of Ocelot Bio, Inc Dr. Bukofzer is guiding the development of novel treatments for complications of severe liver diseases. He was previously Chief Scientific Officer (CSO) of orphan drugs developer Assertio Pharmaceuticals, and Chief Medical Officer (CMO) of Ocera Therapeutics, which developed a novel treatment for hepatic encephalopathy. He held leadership roles with Hospira, Astellas and Abbott.
“VS-01 is an important discovery that could play a pivotal role in treating acute-on-chronic liver failure patients for whom there is no approved treatment,” said Stan Bukofzer, MD.
“It is with great pleasure we welcome Stan as a scientific advisor to Versantis. His experience and expertise in addressing unmet needs of liver disease patients will prove invaluable as we advance clinical development of VS-01 in acute-on-chronic liver failure,” said Prof. Katharina Staufer, MD, CMO of Versantis.